Trevena: Positive Results in Proof-of-Concept Study in COVID-19

 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality

~12 days lower average hospital length of stay in patients treated with TRV027 compared to placebo

TRV027 is currently being evaluated in a randomized controlled study (NIH ACTIV-4) and a global adaptive platform study (REMAP-CAP)

TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

--

Company to host conference call today, September 30th, 2021, at 8:00 a.m. ET

Conference Call and Webcast Information

The Company will host a conference call and webcast with the investment community on September 30, 2021, at 8:00 a.m. Eastern Time featuring remarks by Carrie Bourdow, President and Chief Executive Officer and Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer.

Title:	TRV027 Proof-of-Concept Data Presentation
Date:	Thursday, September 30, 2021
Time:	8:00 a.m. ET
Conference Call Details:	Toll-Free: (855) 465-0180
	International: (484) 756-4313
	Conference ID: 6687853
Webcast:	https://edge.media-server.com/mmc/p/piusmnaa https://finance.yahoo.com/news/trevena-announces-results-trv027-proof-110000150.html